All News
Filter News
Found 809,158 articles
-
Natural Partners and Fullscript plan to merge to create the industry-leading, technology-enabled, wellness management service for integrative healthcare practitioners and patients
6/2/2018
Natural Partners, Inc. and Fullscript announced plans to combine, bringing the best wholesale and fulfillment network in the nutritional supplement industry together with the premier online supplement dispensing platform.
-
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
6/2/2018
New Novartis data from two long-term Treatment-free Remission (TFR) studies in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase (CP) will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
-
NantHealth and NantOmics to Present Data on Three-Fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
6/2/2018
NantHealth and NantOmics will present data on three-fold overestimation of tumor mutation burden (TMB) using a 248 gene list as a panel to impute TMB during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.
-
NantOmics to Present Data for Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
6/2/2018
NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on a genome-based investigation in the neoadjuvant GeparSepto trial for breast cancer treatment during the breast cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.
-
NobleStitch™ EL Continues Expansion Through Europe With Sales Launch In The Netherlands
6/2/2018
NOBLES MEDICAL TECHNOLOGIES II, INC. announced it has officially launched sales in the Netherlands with its first Dutch center performing several successful PFO closure cases at the University Medical Center in Utrecht, Netherlands.
-
NantOmics to Report Data on Cardiac Function in Sarcoma Patients Receiving Aldoxorubicin with Doxorubicin Equivalent Doses over 1000 mg/m2 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
6/2/2018
NantOmics, LLC will present data on cardiac function in patients treated with aldoxorubicin in combination with Doxorubicin during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
-
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
6/2/2018
Puma Biotechnology, Inc. announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 (neratinib) given in combination with the antibody drug conjugate T-DM1 (Kadcyla, ado-trastuzumab emtansine) were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
6/2/2018
AstraZeneca and MedImmune, its global biologics research and development arm presented results from the Phase III (‘1053’) clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell leukemia (HCL) who had received at least two prior lines of therapy.
-
The ink is barely dry on the recently-passed “Right to Try Act,” and the law’s author, Sen. Ron Johnson (R-Wis.) and U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb are butting heads.
-
Amgen, and The University of Texas MD Anderson Cancer Center, announced two multi-year collaborative research deals for a broad range of cancer therapeutics.
-
Neon Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) and hopes to raise $115 million.
-
Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology. Here’s a look at just a few of these stories.
-
FDA Commissioner Scott Gottlieb released a statement on new policies aimed to combat the practice of using certain agency requirements to block timely generic drug entry.
-
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray.
-
June 1st Research Roundup
6/1/2018
There are plenty of great scientific research stories out this week from a tool to delete gene products to the growth of whole muscles incorporated into a biohybrid robot. Here’s a look at just a few of them. -
Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated
6/1/2018
For the 12 months ended April 2018, total U.S. sales of Levofloxacin Oral Solution USP, 25 mg/mL, was approximately $6 million, according to IMS.
-
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)
6/1/2018
TRAZIMERA, a potential biosimilar to Herceptin® (trastuzumab), is Pfizer’s first therapeutic oncology biosimilar to undergo regulatory review in Europe
-
Halyard Health Announces Corporate Rebranding, Changes Name to Avanos Medical, Inc.
6/1/2018
New name and brand underscore a difference in our products, people and processes to deliver game changing innovation in everything we do
-
Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
6/1/2018
Builds on PLG0206 studies published in Nature Scientific Reports.
-
McKesson Completes Acquisition of Medical Specialties Distributors
6/1/2018
McKesson Corporation is a global leader in healthcare supply chain management solutions